Thank you Henrik.
We are building the foundation of Oncopeptides from our commercialization of Pepaxti in Europe. Mid-Term. We are working to add revenue from other geographies. And long term, we are developing our pipeline with current focus on our PDC platform that, as a platform, has a transformative potential for the company by addressing difficult-to-treat tumors such as multiple myeloma, AML, and glioblastoma, to mention a few.
After a slower than expected end to 2025, we are back to a strong growth momentum in Europe, where our current labels stand for a market potential of 1.5 billion SEK. Our pipeline targets the glioblastoma market, which is anticipated to grow due to a very high unmet need, with an estimated global market potential exceeding $8 billion. Looking at some of the announcements in Q1 and how they affect this investment case, we conclude that we have made progress in most areas. As said, we earlier this week announced our intended application to enter the third line of treatment, which would significantly increase the addressable market for Pepaxti.
We have received the first feedback from regulatory authorities on our window of opportunity study, and we are on track to initiate the first clinical study and treat the first patient with glioblastoma this summer. Our ambition to conclude a partnership in Japan remains, and we are also working on other geographies in parallel.
I will, during the presentation, give you an update on our progress during the quarter. Before I go into detail for the different European markets, a look at our sales trajectory. We have experienced some seasonal challenges at the beginning of the year, and we continue to have challenges in Spain with an underperformance during Q1. Despite this, we demonstrated an overall encouraging development, which was primarily due to a strong continued uptake in Italy and an acceleration and step-up from Germany in the second half of the quarter. These are our two largest markets, and it's encouraging to see how they are taking off.
It should be mentioned that Greece continues to deliver and as we anticipated, we got the volumes missing in Q4 ordered in Q1.
All in all, we are satisfied with the development both in Germany, Italy, and Greece. While we need to catch up in Spain.
Approximately 800 patients have been treated since EMA approval in 2022, and the clinical profile of Pepaxti is continuously being confirmed by real-world data published by independent authors. The Pepaxti inclusion in the EHA EMN guidelines with a one B recommendation is important when driving awareness, advocacy and the right positioning of Pepaxti in what has become a complex treatment landscape that is difficult to navigate for many prescribers. We continue to build on the growing body of real-world evidence supporting Pepaxti following its use by doctors across Europe.
Let's have a closer look.
I commonly refer to the fact that our launch is built on a positive clinical experience. So let me walk you through some of the real-world data published that confirms my statement.
Important when looking at real-world data, it always has limitations as it is retrospective, but it does complement clinical trials, and it is gathered from the current treatment landscape and demonstrates real-world safety and effectiveness.
To put the data into context, I wish to remind you that our current label is based on the efficacy data of the HORIZON study, with 29% overall response rate in our target population.
This level is considered clinically meaningful in this late stage population, with a median of prior five lines of treatment. So, looking at the overall picture, these retrospective studies that are all published by external authors confirm Pepaxti effectiveness and that the product has a manageable safety profile in heavily pretreated patients during the first quarter. The first data from Italy was published, which is the second publication from Europe, on how Pepaxti can complement immunotherapy. The Italian data included 17 patients and demonstrated a strong overall response rate of 41%. Interestingly, the response to subsequent immunotherapy treatment was considered clinically meaningful by the authors, as the majority of patients achieved a very good partial response or better.
This means Pepaxti can serve as a bridge between two different immunotherapies, a position that is becoming more and more important.
Furthermore, the Italian data was the first published case of Melflufen as bridging to CAR T with an encouraging complete response as outcome.
Another important real-world data set from Spain, published in 2025, is the other significant data set from Europe.
The Spanish data set includes 19 patients and was generated in an even more frail and late-line population than the Italian patient population.
The Spanish data demonstrates an overall response rate of 28%.
This is very similar to the ORR in our Horizon study, which means that the level of efficacy from our clinical trial data seems valid. Also in today's treatment landscape, which is important to prescribers. We have interesting case studies being published that confirm the therapy is well tolerated in patients with severe renal insufficiency, which is important as many of our patients are old and do have comorbidities. Finally, the Long-Term Responders publication includes patients for whom Pepaxti is making a really big difference. The long term responders published have received between 46 and 83 cycles of treatment, which is important as it is informing clinical decision making and generates confidence in Pepaxti, as well as supports the clinical proof of concept for the entire PDC platform. The long-term responders published have received between 46 and 83 cycles of treatment, which is important as it informs clinical decision-making and generates confidence in Pepaxti, as well as supports the clinical proof of concept for the entire PDC platform.
So in summary, what we see from our RWD data, Pepaxti does serve as a strategic option for patients unable to receive immunotherapy due to frailty or comorbidities.
It is an ideal bridge between immune-based therapies to allow for T-cell recovery. It remains a proven alternative for patients who have relapsed after BCMA CAR T therapies. Now, let's move for a closer look at the performance of our different key markets during Q1. Germany demonstrated strong growth, particularly in the second half of the quarter. As you may recall, we restructured, reduced, and focused our German team on high potential customers in areas with a strong momentum. It is really encouraging to see the effect of these efforts, with a significant step up in new patients starting treatment during one month. In fact, we have seen the number of new patients in March double versus January, and January was at the level of the average month in 2025. With the cost reductions and acceleration in sales, we are on track to reach country-level profitability in Germany during 2026.
Finally, one important announcement we made for Germany in the first quarter was the partnership with IO Medical for the MARINA study, which is an investigator-initiated prospective non-interventional study that is designed to evaluate the real-world effectiveness, safety, and treatment patterns of Pepaxti in our current label population in Germany.
IO Medical is a highly sought after partner, as they have proven effectiveness in executing real-world studies. Partly due to that, they have access to the largest network of office-based physicians. As this graph shows, we are continuing to grow our prescriber base in Germany.
Let's move to Italy.
During Q1, we achieved our target of close to 100% regional access in Italy. The strong uptake is built from a strong foundation with a positive clinical experience, a more centralized prescriber base with more patients per prescriber. And of course, due to an excellent team who has been working really hard to launch and utilize the positive momentum. Pepaxti is currently gaining a strong position in the fourth line in Italy, really complementing immunotherapy, which is exactly the position we are aiming for in all our markets with our current label. The challenging environment in Spain continued during the first quarter.
While we saw a small step up in March, the quarter was, all in all, quite far below expectations.
The doctor strike we commented on in our last quarterly updates continues to influence, resulting in limited access to physicians for Pharma and delayed approval from committees regarding the treatment of late-stage patients. The innovative Multiple Myeloma market segment is overall underperforming in Spain, and this, together with limited access, has created very high competitive pressure between companies during the first quarter.
Being a small company in that environment, we have to focus to succeed in a market that has become difficult to navigate.
One example of focus is that we have been in frequent contact with all the key opinion leaders, and we have together initiated different publications and projects that will support us to position Pepaxti versus immunotherapy to ensure we can catch up on sales in Spain.
We will, in fact, see some very interesting data to support the market being published.
This will take place the upcoming weekend at the Congress in Paris. Strengthened by the potential entry into third line, we will reassess the overall market opportunity in the rest of Europe. And regarding Central Eastern Europe, we have always aimed for a partnership and have advanced our discussions during Q1. We are continuously looking into options for the rest of Europe.
This Monday, we announced our intention to expand Pepaxti into the third line of treatment, and I will now provide a summary.
The rationale behind our decision rests on four key pillars: market expansion. Extended exposure. Clinical value and pricing viability.
We aim to move into the third line and reach less refractory patients, which would at least double the number of addressable patients in Europe compared to our current label.
Clinical data demonstrates that treatment cycles in the third line setting are expected to double on average compared to our current label.
This submission is built on the Phase three Ocean study data, which EMA previously has deemed approvable. What makes us take this decision now is that our assessment of the current treatment landscape indicates that we can now expand without compromising our innovative price level.
To give you an understanding of this decision down to patient level, this chart illustrates the typical journey of multiple myeloma patients from initial diagnosis through successive severe relapses and given all the new treatment options, multiple myeloma has become a marathon with many lines of treatment rather than a short sprint. Today, there is no cure for multiple myeloma, and as you can see, each relapse is accompanied by an increase in tumor burden, meaning the tumor becomes more and more aggressive and difficult to treat. Partly triggered by that, the tumor has to fight against many different modes of action in the earlier lines, which makes it a tough warrior and more and more difficult to beat.
Our current indication is represented by the orange block on the far right, serving patients in advanced disease, specifically those in the fourth line of therapy and beyond who are Triple Class Refractory. At this late stage, the disease burden has already undergone rapid acceleration, and the patients are commonly both old and have become frail by both the tumor, the side effects from previous treatments, and comorbidities. Our goal with this Type II variation is to move that orange block to the left, as shown here. If we expand into the third line, we can, in addition to our current population in fourth line and beyond, also treat patients earlier in their disease course. This is a comparison between our current and potential future indication.
Our current indication is for patients who have received at least three prior lines and are Triple Class Refractory. The potential future indication would target patients who have received at least two prior lines and are refractory to lenalidomide and the last line of therapy. This broader population allows us to bring the benefits of Pepaxti to patients earlier in the treatment journey.
We plan to submit the Type II variation to EMA in the coming months, and we are currently preparing the regulatory documentation needed to submit the application. Initial regulatory feedback is anticipated in the second half of 2026, with a final decision from the European Commission expected in the first half of 2027. We are also starting to prepare market access processes that can be formally initiated post EC decision. This process looks different in various markets, and we will update the financial market on more specifics as we proceed.
Oncopeptides is continuously working to maximize our European sales potential.
For more information, I would like to refer you to our webcast held on Monday, which is available on our website and provides much more information about the historical context and scientific data.
Now let's move outside of Europe. Our negotiations in Japan have taken longer than expected, with several delays during the process that have been out of our control. The treatment landscape is evolving, and from our perspective, the need for a PDC becomes more and more evident in the way that the Pepaxti mode of action complements the immunotherapy. We are eager to conclude a deal to bring the benefit of the PDCs to Japanese patients, which is why we have taken the decision to open up for parallel discussions with multiple partners again.
Regarding partnerships for other parts of the world, we have always seen this as opportunistic.
In the beginning of the year, we hoped for first named patient sales in the Middle East due to some progress in our partner discussions last year. However, currently the situation is unstable in the region, and it is difficult to predict if that is still possible.
Regarding our pipeline, we are now focused on our glioblastoma project and are looking for external collaborations to advance PDCs in other indications. Our PDC platform includes the assets OPD5 and OPDC3. The PDC platform is built on a smart innovation that, through distribution, concentrates killing power inside the cell while sparing healthy tissue. It is specifically engineered to overcome resistance pathways such as p53 mutations that often stop traditional drugs. It is now also clinically validated by approximately 800 patients treated and over 25 million in sales.
This quarter shows that while plenty of potential remains, Pepaxti is being used today and is making a difference for both patients and their relatives. We have taken the first step to broaden the use of PDCs into more difficult-to-treat cancer by targeting new markets like glioblastoma. In the first glioblastoma study, we are working hard to initiate what we call a window of opportunity study. It is a focused study of approximately ten patients to prove human blood-brain barrier penetration. We do this because the blood-brain barrier prevents most drugs from reaching brain tumors, but our PDCs have shown a unique ability to cross this barrier in preclinical models, and we wish to confirm this in humans before we proceed to Phase 1.
It is a fairly low investment that can generate the human proof-of-concept data needed to progress towards the market, with a very high unmet need estimated to grow into an 8 billion USD global market potential. The glioblastoma program has true potential to transform Oncopeptides into a multi-indication global player.
In the first quarter, we achieved regulatory agreement with Swedish and Norwegian agencies for the Window of Opportunity study. We were granted a fast track designation by the Norwegian DMP, enabling an accelerated review process that addresses this life threatening condition.
We have now received the first questions and are still on track to initiate the study during the coming summer. To summarize, we have achieved 91% year over year growth and have a fully approved product with expansion plans that could double the number of addressable patients in Europe and the average number of treatments they go through compared to our current label. We are also strategically expanding through partnerships and targeting major unmet needs like glioblastoma. With that, I would like to thank you for listening, and let's open up for questions.